



Model List of Essential Medicines

Amikacin

Section	Indications
Access group antibiotics Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)	First choice Neutropenia (high-risk) co-prescribed with cefotaxime Acute pyelonephritis (severe) co-prescribed with cefotaxime Inflammatory and other diseases of prostate (severe) co-prescribed with ceftriaxone Acute pyelonephritis (severe) co-prescribed with ceftriaxone Inflammatory and other diseases of prostate (severe)
Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)	
	Second choice co-prescribed with cloxacillin Sepsis without septic shock

Amoxicillin

Section	Indications
Access group antibiotics	
Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid	First choice
Oral > Solid: 250 mg (anhydrous) capsule or tablet; 500 mg (anhydrous) capsule or tablet	Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)
Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid	Acute sinusitis
Oral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate)	Acute otitis media
Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection	Periapical abscess without sinus
Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)	Acute malnutrition in infants, children or adolescents (complicated) [children]
Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)	Chronic obstructive pulmonary disease with acute exacerbation
	Acute malnutrition in infants, children or adolescents (uncomplicated) [children]
	Acute pharyngitis
	co-prescribed with gentamicin
	Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
	co-prescribed with gentamicin
	Sepsis without septic shock
	Second choice
	Bacterial meningitis
	Other indications
	Bacterial infection of unspecified site
	Infectious cystitis

Amoxicillin + clavulanic acid

Section	Indications
Access group antibiotics	
Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection	
Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)	
Oral > Liquid: 250 mg + 62.5 mg per 5 mL powder for oral liquid; 125 mg + 31.25 mg per 5 mL powder for oral liquid	
Oral > Solid: 500 mg + 125 mg tablet	
Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) powder for oral liquid	
Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)	
Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)	
Oral > Liquid: 125 mg + 31.25 mg powder for oral liquid; 250 mg + 62.5 mg powder for oral liquid	
	First choice
	Peritonitis (mild-moderate)
	Bacterial cellulitis, erysipelas or lymphangitis
	Neutropenia (low-risk)
	Other specified pneumonia (Hospital-acquired pneumonia)
	Peritoneal abscess (mild-moderate)
	Infectious cystitis
	Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
	Acute sinusitis
	Chronic obstructive pulmonary disease with acute exacerbation
	Second choice
	Osteomyelitis or osteitis
	Other specified prophylactic measures
	Bacterial infection of joint
	Acute otitis media
	Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)
	co-prescribed with clarithromycin
	Bacterial pneumonia (Community-acquired pneumonia - severe)
	Other indications
	Bacterial infection of unspecified site

Ampicillin

Section	Indications
Access group antibiotics	
Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection	First choice co-prescribed with gentamicin
Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension	Peritoneal abscess (severe) co-prescribed with gentamicin
Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)	Sepsis without septic shock co-prescribed with gentamicin
	Peritoneal abscess (mild-moderate) co-prescribed with gentamicin
	Peritonitis (severe) co-prescribed with gentamicin
	Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with gentamicin
	Peritonitis (mild-moderate) co-prescribed with gentamicin
	Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
	Second choice
	Bacterial meningitis
	Other indications
	Bacterial infection of unspecified site

Benzathine benzylpenicillin

Section	Indications
Access group antibiotics	
Parenteral > General injections > IM: 900 mg in vial benzylpenicillin powder for injection (= 1.2 million IU); 1.44 g in vial benzylpenicillin powder for injection (= 2.4 million IU)	First choice Syphilis Congenital syphilis [children]
	Other indications
	Bacterial infection of unspecified site

Benzylpenicillin

Section	Indications
Access group antibiotics	
Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)	First choice Congenital syphilis [children] Syphilis co-prescribed with gentamicin Sepsis without septic shock co-prescribed with gentamicin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)	Second choice Bacterial meningitis
	Other indications Bacterial infection of unspecified site

Cefalexin

Section	Indications
Access group antibiotics	
Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid	First choice Bacterial cellulitis, erysipelas or lymphangitis
Oral > Solid: 250 mg (as monohydrate)	Second choice Acute pharyngitis
Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)	Chronic obstructive pulmonary disease with acute exacerbation
Oral > Solid > dispersible tablet: 125 mg; 250 mg	Other indications Bacterial infection of unspecified site

Cefazolin

Section	Indications
Access group antibiotics Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection	First choice Other specified prophylactic measures co-prescribed with metronidazole Other specified prophylactic measures
	Second choice Osteomyelitis or osteitis Bacterial infection of joint
	Other indications
	Surgical site infection

Chloramphenicol

Section	Indications
Access group antibiotics Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate) Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection Oral > Liquid: 150 mg per 5 mL (as palmitate) Oral > Solid: 250 mg capsule	Second choice Bacterial meningitis Other indications Bacterial infection of unspecified site

Clindamycin

Section	Indications
Access group antibiotics Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride) Oral > Solid: 150 mg (as hydrochloride) capsule Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate) Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride) Oral > Solid: 150 mg (as hydrochloride)	First choice co-prescribed with piperacillin + tazobactam Necrotising fasciitis Second choice Osteomyelitis or osteitis Bacterial infection of joint Other indications Bacterial infection of unspecified site

Cloxacillin

Section	Indications
Access group antibiotics	
Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid	First choice
Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule	Bacterial infection of joint
PARENTERAL > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection	Osteomyelitis or osteitis
Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid	Bacterial cellulitis, erysipelas or lymphangitis
PARENTERAL > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection	Second choice
Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt)	co-prescribed with amikacin
	Sepsis without septic shock
	Other indications
	Bacterial infection of unspecified site

Doxycycline

Section	Indications
Access group antibiotics	
Oral > Solid: 100 mg (as hyclate)	First choice
PARENTERAL > General injections > unspecified: 100 mg in vial powder for injection	Cholera
Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)	Chlamydia trachomatis
Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)	
Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium)	Second choice
Oral > Solid: 50 mg (as hyclate); 100 mg (as hyclate)	Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)
Oral > Solid > dispersible tablet: 100 mg (as monohydrate)	Cholera [children]
	Chronic obstructive pulmonary disease with acute exacerbation
	Other indications
	Bacterial infection of unspecified site

Gentamicin

Section	Indications
Access group antibiotics	
Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)	
	First choice
	Neonatal meningitis
	co-prescribed with amoxicillin
	Sepsis without septic shock
	co-prescribed with amoxicillin
	Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
	co-prescribed with ampicillin
	Peritoneal abscess (mild-moderate)
	co-prescribed with ampicillin
	Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
	co-prescribed with ampicillin
	Peritoneal abscess (severe)
	co-prescribed with ampicillin
	Peritonitis (severe)
	co-prescribed with ampicillin
	Sepsis without septic shock
	co-prescribed with ampicillin
	Peritonitis (mild-moderate)
	co-prescribed with ampicillin
	Acute malnutrition in infants, children or adolescents (complicated) [children]
	co-prescribed with benzylpenicillin
	Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
	co-prescribed with benzylpenicillin
	Acute malnutrition in infants, children or adolescents (complicated) [children]
	co-prescribed with benzylpenicillin
	Sepsis without septic shock
	Second choice
	Other specified prophylactic measures
	Gonococcal infection
	Other indications
	Bacterial infection of unspecified site

Metronidazole

Section	Indications
Access group antibiotics	
Oral > Liquid: 200 mg per 5 mL (as benzoate)	First choice
Oral > Solid: 200 to 500 mg tablet	Trichomoniasis
PARENTERAL > General injections > unspecified: 500 mg per 100 mL in vial Injection	Intestinal infections due to <i>Clostridioides difficile</i>
Local > Rectal > Suppository: 500 mg suppository; 1 g suppository	co-prescribed with cefazolin
Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg	Other specified prophylactic measures
Local > Rectal > Suppository: 1 g suppository; 500 mg suppository	co-prescribed with cefotaxime
	Peritoneal abscess (mild-moderate)
	co-prescribed with cefotaxime
	Peritoneal abscess (severe)
	co-prescribed with cefotaxime
	Peritonitis (severe)
	co-prescribed with cefotaxime
	Peritonitis (mild-moderate)
	co-prescribed with ceftriaxone
	Peritoneal abscess (mild-moderate)
	co-prescribed with ceftriaxone
	Peritoneal abscess (severe)
	co-prescribed with ceftriaxone
	Peritonitis (mild-moderate)
	co-prescribed with ceftriaxone
	Necrotising fasciitis
	co-prescribed with ceftriaxone
	Peritonitis (severe)
	Second choice
	co-prescribed with ciprofloxacin
	Peritoneal abscess (mild-moderate)
	co-prescribed with ciprofloxacin
	Peritonitis (mild-moderate)
	Other indications
	Bacterial infection of unspecified site

Nitrofurantoin

Section	Indications
<p>Access group antibiotics</p> <p>Oral > Liquid: 25 mg per 5 mL oral liquid</p> <p>Oral > Solid > dosage form: 100 mg; 50 mg</p>	<p>First choice</p> <p>Infectious cystitis</p>

Phenoxytmethylpenicillin

Section	Indications
<p>Access group antibiotics</p> <p>Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid</p> <p>Oral > Solid: 250 mg (as potassium salt) tablet</p> <p>Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)</p>	<p>First choice</p> <p>Acute pharyngitis</p> <p>Periapical abscess without sinus</p> <p>Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)</p> <p>Other indications</p> <p>Bacterial infection of unspecified site</p>

Procaine benzylpenicillin

Section	Indications
<p>Access group antibiotics</p> <p>Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection</p>	<p>First choice</p> <p>Congenital syphilis [children]</p> <p>Second choice</p> <p>Syphilis</p>

Spectinomycin

Section	Indications
<p>Access group antibiotics</p> <p>Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection</p>	<p>Second choice</p> <p>Gonococcal infection</p> <p>Other indications</p> <p>Bacterial infection of unspecified site</p>

Sulfamethoxazole + trimethoprim

Section	Indications
Access group antibiotics	
Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule	First choice Infectious cystitis
Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid	Second choice Infectious gastroenteritis or colitis without specification of infectious agent
Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet	
Oral > Solid > dispersible tablet: 100 mg + 20 mg	Other indications Bacterial infection of unspecified site

Tetracycline

Section	Indications
Access group antibiotics	
Oral > Solid: 250 mg (hydrochloride)	Bacterial infection of unspecified site

Trimethoprim

Section	Indications
Access group antibiotics	
Oral > Liquid: 50 mg per mL	First choice Infectious cystitis
Oral > Solid: 100 mg; 200 mg	